Fast, decisive, low-volume particle characterization analysis for biotherapeutic workflows
When you need the flexibility to conduct particle characterization analyses on different types of biologics, including protein and antibody therapeutics, cell therapies, and gene therapies, the Aura+ System has you covered.
Fully configured to support applications across protein, antibody, cell, and gene therapy workflows, Aura+ brings particle characterization to earlier stages of therapeutic development, so you can make better decisions sooner.
Powered by the backgrounded membrane imaging (BMI) and fluorescence membrane microscopy (FMM) technology shared within the Aura family of instruments, Aura+ System enables applications from late discovery to development and manufacturing, enhancing decision-making and accelerating your success.
Overview
Save precious material with just 5 µL sample volume requirements
Get actionable results from a full 96 well plate of labeled samples to data in just 90 minutes
Boost efficiency with 96-well membrane plate high-throughput capability
Gain deeper particle insights with advanced imaging
Rely only on one platform for proteins, antibodies, and cell and gene therapies development
Recommended Use: For workflows requiring complete flexibility across a full spectrum of analytes, including biologics, viral vectors, cells, and other contaminants.
Take the guesswork out of your aggregate ID
Don’t waste time troubleshooting incorrectly identified aggregates in your therapeutic. Aura+ System uses a combination of brightfield and fluorescent imaging to specifically ID and quantitate cell, viral capsid, protein, degraded excipients,